Anders Hove - ARCA Biopharma Director
| ABIO Stock | USD 3.18 0.05 1.55% |
Director
Dr. Anders Hove, M.D., serves as Director of the Company. Dr. Hove was also appointed to serve on the Boards Nominating and Corporationrationrate Governance Committee. Dr. Hove was most recently a general partner of Venrock Associates, a VC firm, which he joined in January 2004. In 2008, Dr. Hove was a founder of Venrock Healthcare Capital Partners, Venrocks public fund focused on small capitalization biotech companies and latestage private companies. From 1996 to 2004, he was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, LLC, an investment company. Dr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of CibaGeigy. He has served on the Boards of Directors of numerous private and public companies, currently serving on the Boards of two private biopharmaceutical companies since 2017.
| Age | 49 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 10170 Church Ranch Way, Westminster, CO, United States, 80021 |
| Phone | 720 940 2200 |
| Web | https://www.arcabio.com |
ARCA Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1102) % which means that it has lost $0.1102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1357) %, meaning that it created substantial loss on money invested by shareholders. ARCA Biopharma's management efficiency ratios could be used to measure how well ARCA Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -0.15. In addition to that, Return On Capital Employed is likely to drop to -0.21. At this time, ARCA Biopharma's Intangibles To Total Assets are very stable compared to the past year. As of the 16th of April 2024, Asset Turnover is likely to grow to 0.30, while Total Assets are likely to drop about 34.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gaurav Swarup | Instil Bio | 60 | |
| William Ryan | AN2 Therapeutics | 71 | |
| Robert Dixon | AN2 Therapeutics | 60 | |
| Anne Urlwin | Instil Bio | N/A | |
| Charles Fuchs | CytomX Therapeutics | 57 | |
| JeanFrancois Formela | Spero Therapeutics | 60 | |
| Tae Kim | Rezolute | 34 | |
| John Rickard | Instil Bio | N/A | |
| Vimal Vallabh | Instil Bio | N/A | |
| Aloke Banerjee | Instil Bio | 61 | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Elizabeth Tallett | AN2 Therapeutics | 67 | |
| Geoffrey Swier | Instil Bio | N/A | |
| Roger Loeb | Instil Bio | N/A | |
| Casper Breum | Spero Therapeutics | 50 | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Frank Thomas | Spero Therapeutics | 47 | |
| Frederick Gluck | CytomX Therapeutics | 82 | |
| Veena Hingarh | Instil Bio | N/A | |
| Theodore Wang | TRACON Pharmaceuticals | 50 | |
| Martin Mattingly | TRACON Pharmaceuticals | 60 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 |
ARCA Biopharma Leadership Team
Elected by the shareholders, the ARCA Biopharma's board of directors comprises two types of representatives: ARCA Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ARCA. The board's role is to monitor ARCA Biopharma's management team and ensure that shareholders' interests are well served. ARCA Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ARCA Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Ozeroff, Sr. VP, General Counsel and Secretary | ||
| Raymond Woosley, Director | ||
| Brian Selby, Chief Accounting Officer and VP of Fin. | ||
| Thomas Keuer, Chief Officer | ||
| Jeffrey CPA, Chief Officer | ||
| Daniel Mitchell, Director | ||
| Robert Conway, Chairman of the Board | ||
| Linda Grais, Lead Independent Director | ||
| Anders Hove, Director | ||
| Michael Bristow, President CEO, Director |
ARCA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ARCA Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 8.96 M | ||||
| Shares Outstanding | 14.5 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 64.45 % | ||||
| Number Of Shares Shorted | 195.73 K | ||||
| Price To Earning | (0.63) X | ||||
| Price To Book | 1.27 X | ||||
| EBITDA | (7.3 M) |
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ARCA Stock
| 0.8 | JNJ | Johnson Johnson Earnings Call Today | PairCorr |
| 0.67 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.65 | BIIB | Biogen Inc Financial Report 23rd of April 2024 | PairCorr |
| 0.51 | AMGN | Amgen Inc Financial Report 25th of April 2024 | PairCorr |
| 0.43 | REGN | Regeneron Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.